Hematology News

The FDA has revised its deferral policy for blood donations by men who have sex with men and their partners, as well as individuals with tattoos and piercings and other groups, in order to help maintain the blood supply during the , according to a statement from the agency.

Acute and chronic complications of sickle cell disease necessitate frequent interaction with the medical system.

The FDA approved coagulation factor VIIa (recombinant)-jncw for the treatment and control of bleeding episodes among certain adults and adolescents with hemophilia.

Preliminary research has shown the potential of convalescent plasma therapy to improve clinical outcomes of patients with severe disease related to COVID-19.

ASH Research Collaborative’s Data Hub launched an international data registry to help inform care for individuals with blood cancers and COVID-19.

Treatment of venous thromboembolism with oral apixaban was noninferior to subcutaneous dalteparin, without increasing major bleeding risk, according to results from the CARAVAGGIO trial presented at the virtual American College of Cardiology Scientific Session.

The American Red Cross, as well as cancer centers and hospitals across the country, have issued an emergency call for blood donors because of a shortage brought on by various medical and societal complications related to COVID-19.

Deep Vein Thrombosis Awareness Month is observed every March.

The FDA has granted orphan drug designation to therapies for six hematology/oncology drug indications.

Iron chelation therapy with deferasirox conferred a clinically meaningful EFS benefit among transfusion-dependent patients with lower-risk myelodysplastic syndrome, according to results of a randomized phase 2 study published in Annals of Internal Medicine.